SUNNYVALE, Calif., Jan. 27 /PRNewswire/ -- FlowCardia, Inc., a developer of catheter-based systems to treat Chronic Total Occlusions (CTOs) of coronary and peripheral arteries, today announced Mark Stautberg, an experienced medical device executive in the interventional cardiology field, has joined its Board of Directors. Most recently, Stautberg served as Senior Vice President, Sales for Boston Scientific where he was responsible for all of the sales activities in the Cardiology, Peripheral and Vascular Surgery businesses, including the commercialization of Boston’s Taxus drug-eluting stent. Prior to his 13-year career at Boston, Stautberg spent 8 years at Baxter Healthcare in a variety of positions of increasing responsibility.
“Mark’s depth of experience and numerous contacts in the interventional cardiology field will be invaluable to FlowCardia as the CROSSER(TM) System progresses toward U.S. regulatory approval and product launches in Europe and the United States,” said Wick Goodspeed, President and CEO of FlowCardia. “In his work at Boston Scientific, he was a key member of the management team that established Boston as the leading interventional cardiology company in the world.”
“I’m excited to be joining FlowCardia’s Board of Directors and look forward to working with the company’s experienced management team,” said Mr. Stautberg. “FlowCardia’s innovative technology addresses a large unmet need in the Interventional Cath Lab and provides patients with CTOs the opportunity to have their coronary disease treated less invasively.”
FlowCardia, Inc. is a privately held medical device company established in 2002 to develop an effective percutaneous treatment approach for CTOs, one of the last major unresolved clinical challenges in interventional cardiology. FlowCardia’s CROSSER(TM) System utilizes high frequency mechanical vibration to safely and quickly cross CTOs allowing subsequent balloon angioplasty and/or stent placement and obviating the need for potentially traumatic cardiac surgery. Additional information is available on the Company’s Web Site at http://www.flowcardia.com/.
COMPANY CONTACT: Wick Goodspeed 408-617-0352 x-206
FlowCardia, Inc.
CONTACT: Wick Goodspeed of FlowCardia, Inc., +1-408-617-0352, ext. 206
Web site: http://www.flowcardia.com/
